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Purpose: Diabetes mellitus is a condition of considerable concern globally, which can affect 13 
the visual system in various ways, including changes to visual function, the integrity of the 14 
ocular surface and the retinal microcirculation. The aim of this article is to provide an 15 
overview on the perspectives around the relationship between diabetes and refractive status. 16 
Material and Methods: Narrative literature review. 17 
Results: The relationship between diabetes, hyperglycaemia and refractive error has been of 18 
interest to clinicians and researchers for more than a century. This review shows that research 19 
studies investigating the relationship have varied considerably in their design, methodology, 20 
their outcome measures used, as well as their reported results. While some uncertainty 21 
remains, there is evidence that short-term, drastic changes in blood glucose levels affect the 22 
refractive status of human eyes leading to fluctuating and blurred vision.  23 
Conclusion: Patients starting glycaemic treatment or undergoing adaptation to a new 24 
treatment regime may present with considerable refractive changes and visual complaints. 25 
Before considering the prescription of spectacle lenses, clinicians should ideally monitor 26 
patients in whom glycaemic control has been initiated or is being adjusted until a stabilisation 27 
of blood glucose levels has been confirmed. 28 
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ABSTRACT  32 
Zweck: Diabetes Mellitus ist eine Erkrankung von globaler Bedeutung, welche das visuelle 33 
System auf verschiedene Weise beeinträchtigen kann, unter anderem durch Veränderungen 34 
 2 
der Sehfunktion, der okulären Oberfläche und der retinalen Mikrozirkulation. Dieser Artikel 35 
hat zum Ziel einen Überblick über den Zusammenhang zwischen Diabetes und refraktiven 36 
Veränderungen zu geben. 37 
Material und Methoden: Narrativer Literatur-Review. 38 
Ergebnisse: Der Zusammenhang zwischen Diabetes und refraktivem Status ist für Praktiker 39 
und Forscher seit mehr als einem Jahrhundert von Interesse. Studien, welche das Thema 40 
untersuchten, haben eine Vielzahl von Studiendesigns, Methoden, festgelegte 41 
Ergebnisparameter und Ergebnisdarstellungen verwendet. Während weiterhin Unsicherheiten 42 
bestehen bleiben, gibt es Studienergebnisse welche deutlich nachweisen, dass es bei 43 
kurzzeitigen und drastischen Veränderungen des Glukosespiegels im Blut zu kurzfristigen 44 
und erheblichen Fluktuationen des refraktiven Status kommen kann.   45 
Fazit: Patienten, bei welchen eine Einstellung des Glukosespiegel vorgenommen wird, 46 
können erhebliche refraktive Veränderungen subjektiv und störend wahrnehmen. Eine 47 
langfristige Versorgung mit Brillen oder Kontaktlinsen sollte erst in Betracht gezogen 48 
werden, wenn sich der Glukosespiegel stabilisiert hat.  49 
Schlüsselwörter: Diabetes, Refraktion, Refraktionsfehler, Variabilität 50 
 51 
INTRODUCTION 52 
Obtaining information on diabetes mellitus (DM) from patients is a standard element of 53 
history taking prior to refractive assessment and clinical examination of ocular health. Asking 54 
questions about DM allows practitioners to assess the risk of diabetic retinopathy and to put 55 
any refractive complaints, which may be due to poorly controlled hyperglycaemia, into 56 
context. The latter is especially important if a patient has reported a recent temporary 57 
fluctuation in vision, which constitutes a common complaint in patients with DM and 58 
hyperglycaemia.  59 
 60 
Epidemiology and types of diabetes mellitus 61 
DM is a chronic systemic condition and a primary cause of morbidity and mortality globally. 62 
The estimated prevalence in adults worldwide in 2019 was 422 million (8.5%) and around 63 
1.5 million deaths were attributed to the condition.1,2 64 
There are three different types of DM including type 1, type 2 and gestational diabetes. DM 65 
type 1 is rarer than DM type 2 and associated with deficient insulin production, leading to a 66 
need for daily injections of insulin.  The causes of DM type1 are still uncertain and there is 67 
no known prevention available. DM type 2 is considerably more common than DM type 1 68 
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and characterised by what is thought an ineffective use of insulin by the body. It has been 69 
reported that approximately one quarter of adults in the United States have been diagnosed 70 
with DM type 2.3 This type has been shown to be associated with obesity and physical 71 
inactivity as well as genetic factors and processes related to ageing.3 Although DM type 2 72 
used to be a condition that was primarily diagnosed in adults, the World Health Organization 73 
(WHO) reports that it is now more frequently detected in children. Gestational DM refers to 74 
elevated blood sugar levels (hyperglycaemia) above normal values, but below levels of DM, 75 
during pregnancy. This type is considered by the WHO as a risk factor for the development 76 
of DM type 2 later in life.1 77 
 78 
Hyperglycaemia 79 
All types of DM carry health risks that are associated with hyperglycaemia, which describes 80 
an imbalance between glucose production by the body (liver), glucose uptake through 81 
nutrition and glucose uptake by target tissues such as muscle. The imbalance leads to greater 82 
than normal glucose levels, which are used to diagnose DM and to monitor treatment 83 
efficacy.3 To monitor changes, fasting plasma glucose as well as haemoglobin A1c (HbA1c) 84 
levels can be measured.4 85 
 86 
Effect of diabetes and hyperglycaemia on ocular structures 87 
The consequences of DM range from mild systemic and ocular findings to severe and life-88 
threatening complications. These complications include microvascular changes, stroke, 89 
blindness, coronary heart disease, kidney disease and amputations.2 Research studies have 90 
investigated the impact of DM on ocular structures and functions. Several effects on the 91 
ocular surface have been reported, including reduced tear film stability and secretion and 92 
reduced corneal sensitivity.5 Central corneal thickness has been shown to be increased in 93 
DM6,7 and poor glycaemic control can lead to decreased corneal endothelial cell density.7 A 94 
recent major review confirmed that people living with DM have altered corneal endothelial 95 
morphology such as increased pleomorphism, polymegathism and decreased endothelial cell 96 
density. These structural changes appear to be associated with functional changes including 97 
reduced endothelial pump and barrier functions, leading to greater corneal thickness and 98 
hypoxic stress.8 99 
Dry eye has been reported to be common in DM type 29,10 and to be related to a reduction in 100 
quality of life.10 Studies reviewing the associations between DM and peripheral changes have 101 
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suggested that corneal nerve changes due to DM present an opportunity for the early 102 
detection of peripheral neuropathy and early treatment.11  103 
Hyperglycaemia has been shown to cause diabetic keratopathy, but also to be a cause of 104 
retinal and choroidal cell death.12 Recently, lower corneal optical density has been reported in 105 
people with DM in comparison to non-diabetic individuals.13 In contrast to the negative 106 
impact DM can have on the ocular surface, the condition is not thought to be a significant 107 
risk factor for glaucomatous optic neuropathy.14  108 
 109 
However, DM does not only affect the ocular surface and the anterior segment of the ocular 110 
system. Diabetic retinopathy (DR) is a major and potentially sight threatening microvascular 111 
complication of DM affecting the posterior segment. DR represents the leading cause of 112 
preventable blindness in people of working age,15 affecting about a third of people with 113 
DM.16 Hyperglycaemia is commonly the underlying factor for the development of DR, even 114 
though there is a long list of associated risk factors including hypertension, dyslipidaemia, 115 
DM duration and ethnic origin. 15 Early detection of DR is paramount to minimise visual 116 
impairment. To facilitate early detection, diabetic retinal screening programmes are in 117 
operation in many countries and have been shown to be successful and effective in 118 
identifying people developing DR and associated complications such as visual impairment. In 119 
Scotland, a national Diabetic Retinal Screening programme was rolled out in 2006. People 120 
with DM aged 12 years and older are invited to attend either community or hospital-based 121 
retinal screening clinics (note: these are not ophthalmology clinics). Following a brief patient 122 
history and assessment of habitual and best-corrected visual acuity, fundus photographs are 123 
obtained and evaluated to identify clinical signs of DR.17 Patients with non-proliferative 124 
forms of DR are monitored at regular intervals at screening clinics, e.g. at 6- or 12-months 125 
intervals. People with more severe presentations and potentially proliferative DR or signs of 126 
maculopathy are referred for detailed examination at the ophthalmology hospital department. 127 
Overall, about 4% of patients require ophthalmology referral, (once the screening programme 128 
has been fully established). The most common cause for ophthalmology referral is macular 129 
oedema.17 130 
 131 
With both, anterior and posterior ocular structures affected by DM, it seems reasonable and 132 
logical to assume that structural changes may have a noticeable impact on the refractive 133 
status of the visual system. These functional changes are primarily due to underlying 134 




This invited review was devised to provide a succinct overview of the current knowledge and 138 
key aspects of DM and its impact on the refractive system in adult humans. A particular focus 139 
was placed on acute changes in refractive status. 140 
 141 
METHODS 142 
Literature search strategy, inclusion and exclusion criteria 143 
A literature search was carried out on 25 April 2020, using a set of keywords including  144 
‘diabetes’, ‘refraction’, ‘refractive error’, ‘myopia’, ‘hyperopia’ and keyword combinations 145 
to scrutinise the electronic database of the National Library of Medicine (MEDLINE) through 146 
the EBSCO host access at a university library. MEDLINE is a major database and currently 147 
contains more than 27 million references to journal articles in life sciences from more than 148 
5,200 journals, ranging from the year 1966 to the present day. Articles published in English 149 
language and covering the topic of this review were included.  A manual search was 150 
conducted for relevant systematic reviews on the topic, including the Cochrane Database of 151 
Systematic Reviews. The website of the World Health Organization was searched for 152 
relevant reports and general patient information on diabetes mellitus.  153 
 154 
RESULTS 155 
The focus of this review has been on the effect of DM on refraction, which has been 156 
considered for at least a century. Table 1 provides a summary of the included studies and 157 
highlights the various outcome measures that have been reported in studies which 158 
investigated the relationship between refractive error and DM. The studies included in this 159 
review are presented in ascending chronological order by year of publication.  160 
 161 
An early example is a paper by Duke-Elder, who presented a series of three cases that were 162 
examined at St. George’s Hospital in London in the 1920s. In this case series, it is suggested 163 
that a reduction in blood glucose could lead to hyperopic refractive error and an increase in 164 
glucose levels can lead to a more myopic refractive status.18 The first of these cases was a 165 
patient who was admitted to hospital with severe symptoms of DM and the refractive changes 166 
(hyperopic shift) were observed suddenly within a day and followed the start of insulin 167 
therapy, which led to temporary hypoglycaemia. The acute hyperopic shift was found to be 168 
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reversible, but also quite variable during the period in which the insulin dosage (and blood 169 
glucose) was adjusted. 170 
The second case also described a patient who was admitted to hospital in a severe, DM-171 
related health state. Following initiation of insulin treatment, a considerable hyperopic shift 172 
with considerable astigmatism was observed. Similar to the first case, this acute change in 173 
refraction normalised once blood glucose levels had been stabilised and normalised.  174 
The third case was a long-term diabetic patient who was also suffering from what appeared to 175 
have been severe underlying health problems. In this patient, a drastic myopic shift was 176 
observed alongside an increase in blood glucose. Even though no meaningful statistical 177 
analysis can be undertaken based on these three cases, the paper nevertheless presents a 178 
useful insight into early observations of refractive shifts in patients with acute changes in 179 
blood glucose levels.  180 
 181 
More recently, a Danish study was conducted to investigate the impact of DM on refraction 182 
in twins.19 Data were obtained from the Danish Twin Register and a total of 43 twin pairs 183 
were examined. A key outcome of the study was the observation that studies of relations 184 
between refraction and duration of DM showed diverging results. In the monozygotic (MZ) 185 
group, a tendency to reduced axial length and corresponding hyperopia with increasing 186 
duration of DM was found. However, in the dizygotic (DZ) group of same sex twins the 187 
opposite tendency was found. Increasing lens thickness and decreasing anterior chamber 188 
depth with increasing DM duration have been confirmed in this study. The authors conclude 189 
that insulin-dependent DM may influence refractive status on different levels.19 190 
 191 
Okamoto and colleagues observed refractive changes during intensive glycaemic control.20 A 192 
transient hyperopic shift occurred in all 28 participants with a reduction in blood glucose 193 
levels, with a minimum change of 0.50 D and a mean change in refraction of 1.47±0.87 D.  194 
 195 
These findings were confirmed by a clinical study that reported transient variation in 196 
refractive status in diabetic individuals, although no clear trend in either a myopic or 197 
hyperopic direction was observed.21  198 
 199 
Further evidence was provided by a study that investigated the effect of acute 200 
hyperglycaemia on retinal thickness and refraction, which reported that a small hyperopic 201 
shift can occur when acute hyperglycaemia was induced,22 which is in contrast to those 202 
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studies reporting a hyperopic shift during intensive glycaemic control. However, this effect 203 
was observed in only one study participant and the authors concluded that ocular refraction 204 
was not affected by hyperglycaemia. 205 
 206 
Lin and colleagues, in a small case series, also reported transient hyperopia due to intensive 207 
glucose reduction.4 208 
 209 
Another paper considered and reviewed aspects around the crystalline lens in relation to 210 
blood glucose levels.23 The authors discuss refractive index gradients within the lens and 211 
applied mathematical modelling to determine whether and how such gradients impact on 212 
refraction. In their paper, they report that there is no simple linear correlation between blood 213 
glucose and refraction, at least in relation to short-term changes over several weeks. 214 
Even though the authors discuss recent work, which suggests that starting therapy to control 215 
hyperglycaemia leads to a hyperopic shift within a few days to weeks, followed by a gradual 216 
return to baseline over a several weeks to months, they conclude that refractive changes occur 217 
relatively slowly (several weeks) and suggest that the transient nature implies that two 218 
mechanisms are involved. The absence of axial changes or curvature changes of ocular 219 
components suggests that changes in refractive index indeed play a role. In summary, the 220 
important finding was that it appears possible to account for any observed hyperopic shift 221 
after initiation of therapy for hyperglycaemia and the subsequent recovery based on changes 222 
in the distribution of refractive index within the lens.23 223 
 224 
Huntjens, Charman and colleagues carried out a study to investigate how short term changes 225 
in blood glucose affect refractive components in individuals with type 1 and type 2 DM.24 226 
For this clinical study, 41 long-term diabetic and 20 non-diabetic (control) participants were 227 
recruited and data were collected throughout the day at broadly two-hourly intervals  between 228 
8.00 and 20.00 hours. Various clinical measurements including objective refraction, 229 
aberrations, anterior chamber depth, lens thickness and corneal thickness were collected, one 230 
eye of each participant was randomly selected for statistical analysis. The study showed that 231 
short-term fluctuations of blood glucose levels did not cause acute changes in refractive error, 232 
aberrations, or anterior biometric parameters.24 233 
 234 
In a recent ex-vivo study, a bovine lens model was used to assess optical changes in 235 
hyperglycaemia as well as in response to reductions in hyperglycaemia (back to normal 236 
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glucose levels, simulating treatment onset).25 Back vertex focusing distance and equatorial 237 
lens diameter were measured. From these data back vertex focal length and longitudinal 238 
spherical aberration were derived. A statistically non-significant trend towards myopia with 239 
increasing hyperglycaemia was observed. Similarly, a hyperopic shift was noted for changes 240 
from hyperglycaemia to normal glucose levels, which was also not statistically significant. 241 
Overall, the results suggest that there is no consistent crystalline lens induced refractive 242 
change following exposure to hyperglycaemia for periods of up to 5 days.25 243 
 244 
Zhu and colleagues assessed the frequency of under-corrected refractive error among diabetic 245 
individuals in Shanghai, China.26 Data were collected through a community-based study that 246 
involved a survey of 649 people aged 60 years and older living with DM. A range of clinical 247 
measurements was carried out including refraction, best-corrected visual acuity, tonometry, 248 
slit-lamp biomicroscopy and fundus photography. A key finding of the study was the 249 
observation that undercorrected refractive error occurred in approximately 17% of the 250 
participants, thus providing an indirect indication of a possible link between DM and 251 
refractive status.26 Similar studies have been carried out, for example in India, where a high 252 
prevalence of refractive error was observed in diabetic individuals (type 2) aged 40 years and 253 
older.27 254 
 255 
In another study carried out in China, Song et al. set out to determine the prevalence of 256 
refractive error and the association with glycaemic control in adults living with type 2 DM.28 257 
A total of 839 participants were included in the analysis, 96% of whom presented with some 258 
form of refractive error.  Haemoglobin A1C (HbA1C) levels were found to be associated with 259 
refractive status in that myopic individuals had higher and hyperopic individuals lower levels 260 
of HbA1C. Overall, this may provide some, albeit not necessarily robust, evidence of a 261 
potential link between glycaemic control and refractive error and the authors recommend 262 
further longitudinal research to assess the relationship between glycaemic control and 263 
refractive status over time.28  264 
 265 
DISCUSSION AND CONCLUSIONS 266 
The impact of poor glycaemic control and hyperglycaemia on the refractive status in humans 267 
has been a topic of interest to the clinical and research community for at least a century. Yet, 268 
the studies reviewed here provide examples of the diversity of study designs, research 269 
methods, outcome measures used and resultant findings. For example, study designs included 270 
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observational case series,18 4 cohort studies,19 clinical cross-sectional studies using human 271 
participants,4,20–22  population-based studies,26 ex-vivo animal studies25 and mathematical 272 
modelling studies.23 The variety of study designs and methodological approaches applied 273 
makes a direct comparison of the outcomes difficult. However, together these studies indicate 274 
that there is remaining uncertainty and that there is no consistent or robust association 275 
between glycaemic status, glycaemic control and refractive error, or changes in refraction.  276 
However, there seems to be sufficient evidence to support the notion that short-term and 277 
reversible changes in refraction can occur in some individuals, for example in situations 278 
where blood glucose levels either drop or rise drastically. Similarly, the initiation of treatment 279 
to normalise blood glucose levels appears to cause a change in refraction, frequently in the 280 
form of a hyperopic shift. These refractive changes are not usually long-lasting and should 281 
thus not be considered in the long-term refractive management of patients.   282 
The time course of the refractive changes varies, but the studies reviewed indicate reasonably 283 
strongly that a stabilisation of refractive status can be achieved within weeks of initiating or 284 
adjusting normoglycaemic treatments. The exact timeline needs to be determined for each 285 
individual patient. To determine the time point of refractive stability, regular follow-up 286 
appointments to assess the refractive status should be arranged, e.g. at 2-4 weekly review 287 
intervals, but always dependent on the individual situation of the patient. These follow-up 288 
appointments would allow for any trends such as any hyperopic shifts to be measured. 289 
Ophthalmic appointments could be coordinated in line with general medical appointments, 290 
potentially facilitating comparative assessments of blood glucose and refraction monitoring 291 
(where feasible).  292 
Even though it is not possible to provide a definitive guide on when exactly refractive 293 
stability will be achieved, clinicians should ideally monitor patients in whom glycaemic 294 
control has been initiated or is being considerably adjusted and wait for a stabilisation of 295 
blood glucose levels before considering the prescription of spectacle lenses. Communicating 296 
the need to wait to patients is critical to ensure patients are fully aware of the reasons their 297 
visual problems are not being managed with spectacles immediately. The monitoring of 298 
blood glucose and its stabilisation are typically overseen by general medical practitioners or 299 
DM specialists. If patients present with visual complains and unmet refractive needs, there is 300 
an opportunity for interdisciplinary, collaborative care of such patients, involving close 301 
communication between optometrist and medical practitioner as well as the exploration of 302 
short-term solutions for the patient in order to help them achieving best possible visual 303 
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outcomes while their glucose levels are being brought under control and spectacle prescribing 304 
can commence.  305 
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Table 1. Summary of key characteristics of included articles.  415 
 416 
First author Year Main outcome measures Effect of changes in 
blood glucose levels 
directly measured? 
 
Duke-Elder 1925  Refractive error 
 
Yes 
Løgstrup 1997  Refractive error 
 Axial length 
 Corneal radius  
 Lens thickness 




Okamoto  2000  Plasma glucose levels 
 Onset and peak of hyperopic 
change 
 Baseline refraction 
 Change in refraction 
 
Yes 
Sonmez 2005  Plasma glucose levels 
 Baseline refraction 
 Lens power 
 
Yes 
Wiemer  2008  Change in refraction 
 Retinal thickness 
 
Yes 
Lin 2009  Baseline refraction 
 Change in refraction 
 
Yes 
Rani 2010  Refractive error (prevalence) 




Charman 2012  Crystalline lens model 
 
No 
Huntjens 2012  Mean spherical equivalent 
 Central corneal thickness 




Mehta  2015  Bovine lens model, ex-vivo 
 Back vertex focusing distance 
 Equatorial lens diameter 
 
Yes 
Zhu 2017  Refractive error (prevalence) 
 Visual acuity 
 Intraocular pressure 
 Odds ratios 
 
No 
Song 2018  Refractive error (prevalence) 
 
No 
 417 
